Henrickson Nauta Wealth Advisors Inc. Has $991,000 Stock Holdings in Gilead Sciences, Inc. $GILD

Henrickson Nauta Wealth Advisors Inc. trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 49.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,112 shares of the biopharmaceutical company’s stock after selling 7,013 shares during the quarter. Henrickson Nauta Wealth Advisors Inc.’s holdings in Gilead Sciences were worth $991,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Aviva PLC boosted its stake in shares of Gilead Sciences by 5.4% during the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock worth $141,978,000 after acquiring an additional 59,782 shares during the period. Nordea Investment Management AB raised its stake in Gilead Sciences by 16.5% in the 4th quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after acquiring an additional 726,101 shares during the period. Life Cycle Investment Partners Ltd bought a new stake in Gilead Sciences in the 4th quarter valued at $1,418,000. Beacon Investment Advisory Services Inc. lifted its holdings in Gilead Sciences by 10.3% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 111,531 shares of the biopharmaceutical company’s stock valued at $13,689,000 after purchasing an additional 10,449 shares during the last quarter. Finally, SageView Advisory Group LLC boosted its position in Gilead Sciences by 159.5% during the third quarter. SageView Advisory Group LLC now owns 23,940 shares of the biopharmaceutical company’s stock worth $2,657,000 after purchasing an additional 14,715 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on GILD shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research report on Tuesday, June 16th. Daiwa Securities Group reduced their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Gilead Sciences in a research note on Monday, June 8th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Finally, Truist Financial restated a “buy” rating and set a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $158.41.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the sale, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. This represents a 1.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 68,000 shares of company stock worth $8,930,150. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $123.76 on Monday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The firm has a 50-day moving average of $131.66 and a 200-day moving average of $134.28. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The stock has a market cap of $153.66 billion, a PE ratio of 16.86 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.